The Latest Breaking News from biotech

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

Robust government support coupled with rapid tech advancements is bolstering the biotech sector. Hence, investors eyeing growth might buy fundamentally solid biotech stocks Theratechnologies (THTX), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), with massive growth potential. Read on.

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

The biotech industry’s growth prospects look promising due to considerable investments in research and development (R&D), an innovative drugs pipeline, government initiatives, the growing popularity of personalized medicine, drug approvals, expanding healthcare needs, etc. Amid this backdrop, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), Foghorn Therapeutics (FHTX),…

The biotechnology industry is experiencing significant growth, fueled by government initiatives, rising investments and tech advancements. Therefore, it could be wise to consider fundamentally strong biotech stocks Shionogi & Co (SGIOY), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), which are making major moves on wall street. Read more.

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on….

The biotech industry is poised for robust growth thanks to the increasing demand for personalized treatments, the rise in chronic diseases, a rapidly aging population, the adoption of advanced technologies, and government initiatives. Therefore, to capitalize on the industry’s growth prospects, one could consider buying fundamentally strong biotech stocks Genmab…

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

With technology revolutionizing drug discovery, the biotech sector thrives on innovation and breakthrough therapies. Hence, let's delve into and analyze the gain potential of fundamentally strong biotech stocks Amgen (AMGN), Alkermes (ALKS), and Vertex Pharmaceuticals (VRTX). Read more….

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

The biotech industry is well-positioned for solid growth thanks to the increasing demand for effective treatments for chronic diseases, a rapidly aging population, the adoption of technologies like AI, and government initiatives. To capitalize on the biotech industry’s growth prospects, should one consider investing in biotech stocks Puma Biotechnology (PBYI),…